OUTCOME OF PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION DISCHARGE ON NEUROHORMONAL ANTAGONIST

Introduction: Heart failure (HF) is an important health problem with elevated socio-health care costs. This disease is highly prevalent in the people over the age of 65 years and constitutes the first cause of hospitalization in this population. Objectives: The main objective of the study is to find the outcome of patients with heart failure with preserved ejection fraction discharge on neurohormonal antagonist. Material and methods: This randomized control trial was conducted in QAMC Bahawalpur during June 2021 to November 2021. The data was collected with the permission of ethical committee of hospital. The present analysis included all patients discharged alive after an episode of AHF with a LVEF of 50% or more recorded in an echocardiography performed during the 6 months prior to decompensation or that had been recorded during the current admission. Results: The data was collected from 100 patients of both genders. The mean age was 82.45 ± 4.56 years. The group receiving ANHD was younger, had a higher presence of hypertension, diabetes mellitus and ischemic cardiomyopathy, less functional capacity, and decompensation was more frequent due to tachyarrhythmia, hypertensive crisis or incompliance with pharmacological or dietetic treatments. Conclusion: It is concluded that anti-neuro hormonal drugs do not seem to reduce mortality or adverse events preserved ejection fraction patients, only renin-angiotensin-aldosterone-system inhibitors could provide some benefits, reducing the risk of hospitalization for AHF